Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $401.19 | 13 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $117.74 | 1 | $0 (2017) |
| Celgene Corporation | $64.58 | 1 | $0 (2019) |
| PruGen, Inc. Pharmaceuticals | $51.00 | 4 | $0 (2017) |
| UCB, Inc. | $50.00 | 1 | $0 (2019) |
| PFIZER INC. | $43.43 | 3 | $0 (2017) |
| Valeant Pharmaceuticals North America LLC | $40.06 | 2 | $0 (2017) |
| Allergan Inc. | $34.38 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $114.58 | 2 | Celgene Corporation ($64.58) |
| 2018 | $34.38 | 1 | Allergan Inc. ($34.38) |
| 2017 | $252.23 | 10 | Galderma Laboratories, L.P. ($117.74) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/29/2019 | Celgene Corporation | Otezla (Drug) | Food and Beverage | Cash or cash equivalent | $64.58 | General |
| Category: Dermatology | ||||||
| 01/28/2019 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Immunology | ||||||
| 01/13/2018 | Allergan Inc. | RHOFADE (Drug) | Food and Beverage | In-kind items and services | $34.38 | General |
| Category: DERMATOLOGY | ||||||
| 12/07/2017 | PruGen, Inc. Pharmaceuticals | — | Food and Beverage | Cash or cash equivalent | $17.00 | General |
| 08/09/2017 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $11.33 | General |
| Category: DERMATOLOGY | ||||||
| 08/03/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/19/2017 | PruGen, Inc. Pharmaceuticals | — | Food and Beverage | Cash or cash equivalent | $7.00 | General |
| 06/21/2017 | PruGen, Inc. Pharmaceuticals | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 04/18/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/17/2017 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: DERMATOLOGY | ||||||
| 03/01/2017 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: DERMATOLOGY | ||||||
| 02/22/2017 | PruGen, Inc. Pharmaceuticals | — | Food and Beverage | Cash or cash equivalent | $12.00 | General |
| 01/14/2017 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug) | Food and Beverage | In-kind items and services | $117.74 | General |
| Category: ACNE | ||||||
About Dr. Barbara Ebert, MD
Dr. Barbara Ebert, MD is a Dermatology healthcare provider based in Moultrie, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558319301.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barbara Ebert, MD has received a total of $401.19 in payments from pharmaceutical and medical device companies, with $114.58 received in 2019. These payments were reported across 13 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($401.19).
Practice Information
- Specialty Dermatology
- Location Moultrie, GA
- Active Since 05/04/2006
- Last Updated 07/21/2022
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1558319301
Products in Payments
- EPIDUO FORTE (Drug) $117.74
- Otezla (Drug) $64.58
- Cimzia (Drug) $50.00
- EUCRISA (Drug) $43.43
- XIFAXAN (Drug) $40.06
- RHOFADE (Drug) $34.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.